102 related articles for article (PubMed ID: 29023897)
21. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
22. Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer.
Kumar D; Gupta D; Shankar S; Srivastava RK
Oncotarget; 2015 Feb; 6(5):3280-91. PubMed ID: 25682864
[TBL] [Abstract][Full Text] [Related]
23. Cervical cancer: Biomarkers for diagnosis and treatment.
Dasari S; Wudayagiri R; Valluru L
Clin Chim Acta; 2015 May; 445():7-11. PubMed ID: 25773118
[TBL] [Abstract][Full Text] [Related]
24. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models.
Suetsugu A; Honma K; Saji S; Moriwaki H; Ochiya T; Hoffman RM
Adv Drug Deliv Rev; 2013 Mar; 65(3):383-90. PubMed ID: 22921594
[TBL] [Abstract][Full Text] [Related]
25. Characterization of LMX-1A as a metastasis suppressor in cervical cancer.
Liu CY; Chao TK; Su PH; Lee HY; Shih YL; Su HY; Chu TY; Yu MH; Lin YW; Lai HC
J Pathol; 2009 Oct; 219(2):222-31. PubMed ID: 19644956
[TBL] [Abstract][Full Text] [Related]
26. Exosome levels in human body fluids: A tumor marker by themselves?
Cappello F; Logozzi M; Campanella C; Bavisotto CC; Marcilla A; Properzi F; Fais S
Eur J Pharm Sci; 2017 Jan; 96():93-98. PubMed ID: 27640113
[TBL] [Abstract][Full Text] [Related]
27. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
[TBL] [Abstract][Full Text] [Related]
28. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of Arhgap6 on cervical carcinoma cells.
Li J; Liu Y; Yin Y
Tumour Biol; 2016 Feb; 37(2):1411-25. PubMed ID: 26628301
[TBL] [Abstract][Full Text] [Related]
30. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic technologies for circulating tumour cells and exosomes.
Shao H; Chung J; Issadore D
Biosci Rep; 2015 Nov; 36(1):e00292. PubMed ID: 26604322
[TBL] [Abstract][Full Text] [Related]
32. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.
Nijhuis ER; Nijman HW; Oien KA; Bell A; ten Hoor KA; Reesink-Peters N; Boezen HM; Hollema H; van der Zee AG
J Clin Pathol; 2007 Jul; 60(7):824-30. PubMed ID: 17596548
[TBL] [Abstract][Full Text] [Related]
33. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
34. Characterization and proteomic analysis of ovarian cancer-derived exosomes.
Liang B; Peng P; Chen S; Li L; Zhang M; Cao D; Yang J; Li H; Gui T; Li X; Shen K
J Proteomics; 2013 Mar; 80():171-82. PubMed ID: 23333927
[TBL] [Abstract][Full Text] [Related]
35. NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.
Niu C; Sun X; Zhang W; Li H; Xu L; Li J; Xu B; Zhang Y
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775588
[TBL] [Abstract][Full Text] [Related]
36. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
Madhavan B; Yue S; Galli U; Rana S; Gross W; Müller M; Giese NA; Kalthoff H; Becker T; Büchler MW; Zöller M
Int J Cancer; 2015 Jun; 136(11):2616-27. PubMed ID: 25388097
[TBL] [Abstract][Full Text] [Related]
37. Targeting Overexpressed Activating Transcription Factor 1 (ATF1) Inhibits Proliferation and Migration and Enhances Sensitivity to Paclitaxel In Esophageal Cancer Cells.
Hao Q; Zhao X; Zhang Y; Dong Z; Hu T; Chen P
Med Sci Monit Basic Res; 2017 Sep; 23():304-312. PubMed ID: 28912415
[TBL] [Abstract][Full Text] [Related]
38. Double-stranded DNA in exosomes: a novel biomarker in cancer detection.
Thakur BK; Zhang H; Becker A; Matei I; Huang Y; Costa-Silva B; Zheng Y; Hoshino A; Brazier H; Xiang J; Williams C; Rodriguez-Barrueco R; Silva JM; Zhang W; Hearn S; Elemento O; Paknejad N; Manova-Todorova K; Welte K; Bromberg J; Peinado H; Lyden D
Cell Res; 2014 Jun; 24(6):766-9. PubMed ID: 24710597
[No Abstract] [Full Text] [Related]
39. Near-Infrared Afterglow Semiconducting Nano-Polycomplexes for the Multiplex Differentiation of Cancer Exosomes.
Lyu Y; Cui D; Huang J; Fan W; Miao Y; Pu K
Angew Chem Int Ed Engl; 2019 Apr; 58(15):4983-4987. PubMed ID: 30702188
[TBL] [Abstract][Full Text] [Related]
40. Mutant proteins as cancer-specific biomarkers.
Wang Q; Chaerkady R; Wu J; Hwang HJ; Papadopoulos N; Kopelovich L; Maitra A; Matthaei H; Eshleman JR; Hruban RH; Kinzler KW; Pandey A; Vogelstein B
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2444-9. PubMed ID: 21248225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
